title: A herpes simplex virus type 1 mutant with a deletion immediately upstream of the LAT locus establishes latency and reactivates from latently infected mice with normal kinetics.
abstract: The latency associated transcripts (LATs) are the only abundant viral gene products detected during latent herpes simplex virus (HSV) infection of peripheral nerves in animals and people. A LAT promoter has been identified and mutant viruses with lesions removing the promoter and surrounding region have been observed to reactivate slowly from trigeminal ganglia (TG) explanted from latently infected mice. Previous work has shown that most mutants with lesions limited to regions downstream of the LAT promoter reactivate normally. Therefore, to help map the boundaries of the slow reactivation phenotype, a mutant virus with lesions located immediately upstream of the LAT promoter was constructed and called 17 delta S/N. 17 delta S/N contains a 437 nucleotide (nt) deletion 332 nts upstream of the TATAA box of the LAT promoter. In productively infected cells, 17 delta S/N failed to synthesize detectable amounts of the 1.1 and 1.8 kb transcripts which are produced during wild-type infections and are specified by a region just upstream of the LAT promoter. However, 17 delta S/N did produce normal amounts of LAT in tissue culture as well as in neurons derived from latently infected cells, as ascertained by Northern blot and in situ hybridization analysis. Moreover, in latently infected mice, 17 delta S/N established and maintained infection in as many neurons as did wild type virus, as determined by in situ polymerase chain reaction (PCR) to detect viral DNA. Finally, the virus reactivated from TG derived from latently infected mice with kinetics indistinguishable from those of wild-type virus. Therefore, reactivation from latency, in this model system, does not appear to require function from the viral genomic region located immediately upstream of the LAT promoter.
authors.affiliation: Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107-6799, USA.
authors.forename: J
authors.initials: J
authors.lastname: Maggioncalda
authors.forename: A
authors.initials: A
authors.lastname: Mehta
authors.forename: O
authors.initials: O
authors.lastname: Bagasra
authors.forename: N W
authors.initials: NW
authors.lastname: Fraser
authors.forename: T M
authors.initials: TM
authors.lastname: Block
mesh_terms: D000818:Animals; D015152:Blotting, Northern; D015139:Blotting, Southern; D002478:Cells, Cultured / Q000502:physiology / Q000821:virology; D046508:Culture Techniques; D004279:DNA, Viral / Q000235:genetics; D015252:Deoxyribonucleases, Type II Site-Specific; D005260:Female; D017353:Gene Deletion; D016679:Genome, Viral; D005838:Genotype; D006566:Herpesviridae Infections / Q000235:genetics*; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000502:physiology*; D007700:Kinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation / Q000502:physiology; D010641:Phenotype; D011401:Promoter Regions, Genetic / Q000235:genetics; D014158:Transcription, Genetic / Q000235:genetics; D012668:Trigeminal Ganglion / Q000166:cytology / Q000821:virology; D017735:Virus Latency
chemical_list: D004279:DNA, Viral; C045874:endodeoxyribonuclease StyI; D015252:Deoxyribonucleases, Type II Site-Specific; C038565:GCGGCCGC-specific type II deoxyribonucleases